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THE ‘‘SIDE-POPULATION’’ OF HUMAN LYMPHOMA CELLS HAVE IN-
CREASED CHEMO-RESISTANCE, STEM-CELL LIKE PROPERTIES AND
ARE POTENTIAL TARGETS FOR IMMUNOTHERAPY
Shafer, J.A.1,2, Leen, A.M.1,2, Cruz, R.1,2, Craddock, J.A.1,2,
Heslop, H.E.1,2, Rooney, C.M.1,2, Brenner, M.K.1,2, Bollard, C.M.1,2,
Foster, A.E.1,2 1 Baylor College of Medicine, Houston, TX; 2 Baylor College
of Medicine, Houston, TX
We have previously demonstrated that hematological malignan-
cies contain a distinct ‘‘side-population’’ (SP), which is character-
ized by the active transport of Hoechst fluorescent dye. The
mechanisms responsible for Hoechst efflux contribute to SP resis-
tance to chemotherapy and SP have been shown to be enriched for
tumor initiating cells in several human cancer models. We hypoth-
esize that targeting the cancer ‘‘SP’’ cells using immunotherapy may
prevent relapse by eliminating the cell population that is chemore-
sistant and has tumor repopulating potential. We characterized SP
cells in 11 human lymphoma cell lines. 5/11 lymphoma cell lines
had a distinct SP ranging from 0.8–2% of total cells. We subse-
quently found SP cells with tumor associated antigens (TAAs) in
biopsy samples from patients with Hodgkin’s Lymphoma, T-cell
Lymphoma, and Follicular lymphoma. Culture of the sorted cell
lines show that SP but not the non-SP cells produced progeny
that were both SP and non-SP cells. Gene expression analysis of
the SP showed increased expression of ABC transporters that me-
diate transport of some chemotherapeutic agents out of the cell.
We evaluated whether lymphoma cell lines with a SP are resistant
to the chemotherapeutic drug gemcitabine. The viability of lym-
phoma lines containing SP cells was markedly higher (mean
59.8%; range 37.4–87.8) than the viability of lines without a SP
(mean 9.3% range 3.0%–12.2) when cultured with 10nM gemcita-
bine for 3 days. The SP component of the lymphoma cells became
enriched 10-fold when cultured with gemcitabine. Moreover, when
equal numbers of SP and non-SP cells were grown in separate frac-
tions with gemcitabine, there was reduced viability of the non-SP
(mean 2,2476 294 cpm) by thymidine assay. In contrast, the viabil-
ity of the SP was preserved (mean 13,200 6 7500 cpm). Although
lymphoma SP cells are resistant to chemotherapeutic agents, they
also express higher levels of TAAs that are known targets for cyto-
toxic T-cells. RT-PCR and immunohistochemistry both show that
SP cells are HLA positive and have increased expression of TAAs
(e.g. MAGEA, SSX, PRAME) transcripts and protein compared
to non-SP cells from the same tumor. We have generated T-cells
that recognize these TAAs and have shown they can recognize
and kill SP targets. Hence, lymphoma cell lines and primary lym-
phoma tissue contain chemotherapy-resistant SP cells which
express tumor associated antigens and may be targeted by specific
T cells.180
REDUCED-INTENSITY ALLOGENEIC VERSUS AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HODGKIN’S
AND NON-HODGKIN’S LYMPHOMA
Gutierrez-Aguirre, C.H.1, Cantu-Rodriguez, O.G.1, Gonzalez-
Llano, O.1, Jaime-Perez, J.C.1, Salazar-Riojas, R.1, Martinez-
Gonzalez, O.L.1, Gutierrez-Riverol, K.I.2, Ruiz-Delgado, G.J.2,
Ruiz-Arguelles, G.J.2, Gomez-Almaguer, D.1 1 Hospital Universitario
de La U.A.N.L., Monterrey, Nuevo Leon, Mexico; 2 Centro de Hematolo-
gia y Medicina Interna de Puebla, Puebla, Mexico
Introduction: The role of reduced-intensity conditioning alloge-
neic stem cell transplantation (allo- RICSCT) compared with high-
dose chemotherapy followed by autologous stem cell transplantation
(auto-SCT) in Hodgkin’s disease (HD) and in non Hodgkin’s lym-
phoma (NHL) patients remains poorly defined. We retrospectively
analyzed the outcome of 71 patients with advanced disease who re-
ceived one of both treatments, 39 patients with NHL and 32 with
HD. Twenty three NHL patients and 14 HD patients received an
allo-RICSCT using fludarabine-cyclophosphamide-low dose busul-
fan as conditioning regimen. Sixteen NHL patients and 18 HD pa-
tients received auto-SCT using cyclophosphamide and etoposide as
conditioning regimen.
Results: (see table 1).Table 1
NHL 1 Allo NHL 1 Auto HD 1 Allo HD 1 AutoAge (median) years 47 56 26 26
Disease stage
before SCT
1st remission 0 7 (44%) 1 (7%) 3 (17%)
2nd remission 8 (35%) 2 (12%) 0 3 (17%)
Refractory 16 (65%) 7 (44%) 13 (93%) 12 (66%)
Ann Arbor I-II 5 (22%) 7 (44%) 0 6 (33%)
Ann Arbor III-IV 18 (78%) 9 (56%) 14 (100%) 12 (67%)
B symptoms 65% 75% 85% 89%
CD341 cells
infused5  106 2.2  106 4.5  106 3  106aEICH / cEICH 39% / 31% — 14% / 7% —
Overall survival 69% 81% 36% 65%
Death 7 (31%) 3 (19%) 9 (64%) 7 (35%)
Relapse 4 (17%) 5 (31%) 7 (50%) 11 (61%)
Relapse as cause
of death3(42%) 1(33%) 7 (78%) 7 (100%)n5 23 16 14 18Characteristics of the patients included and results. Conclutions:
We found significant difference in overall survival between allo-
RICSCT recipients and auto-SCT recipients and also a higher
mortality in HD patients and in NHL patients who received an
allo-RICSCT. The relapse rate was higher in autografted patients,
both in NHL an HD, even in patients in first remission. We con-
clude that both therapeutic modalities may be useful in refractory
NHL patients and seems that in refractory HD the results were
better using autologous grafts.181
PRE-MOBILIZATION BONE MARROW PLASMACYTOSIS PREDICTS
SUCCESSFUL STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE
MYELOMA RECEIVING LENALIDOMIDE-BASED INDUCTION REGIMENS
Benson, D.M.1, Hofmeister, C.C.1, Hamadani, M.1, Panzner, K.1,
Smith, M.K.3, Penza, S.L.1, Elder, P.2, Krugh, D.2, O’Donnell, L.2,
Devine, S.M.1 1The Ohio State University, Columbus, OH; 2The Ohio State
University, Columbus, OH; 3 The Ohio State University, Columbus, OH
High-dose chemotherapy (HDC) with autologous stem cell trans-
plant (ASCT) remains a crucial therapeutic option for many patients
with multiple myeloma (MM). Although thalidomide, lenalidomide
and bortezomib may be associated with improved outcomes
compared with traditional therapies, how to best integrate novel
agents into a treatment plan incorporating HDC/ASCT remains
unknown. Moreover, recent studies have suggested that the use of
lenalidomide, in particular, may impair subsequent ability to harvest
stem cells for ASCT. We examined our institutional experience in
287 sequential patients with MM who underwent HDC/ASCT
from 1992 to 2008 stratified by the type of induction regimen re-
ceived prior to HDC/ASCT: chemotherapy-based (e.g., VAD,
DVD) or novel agent-based (thalidomide, lenalidomide, or bortezo-
mib). Patients were similar in age, Durie Salmon and ISS stage,
high-risk karyotype/FISH status, and other variables. Time from di-
agnosis to mobilization was similar and no differences were seen in
remission status at time of stem cell mobilization. However, success-
fully mobilized patients who received induction regimens containing
a novel agent had lower pre-mobilization marrow plasmacytosis
(mean 12.9% 6 SD 16) than patients who received chemotherapy-
based inductions (mean 22%6 27, p5 0.001), yet total marrow cel-
lularity was similar between groups. Controlling for other variables
(e.g., use of cyclophosphamide for mobilization and prior radiation
exposure), pre-mobilization marrow plasmacytosis predicted the
chances of successful stem cell mobilization in patients who received
induction with lenalidomide: successfully mobilized patients had less
marrow plasma cells pre-mobilization (5% 6 8) than patients who
failed mobilization (21% 6 1.2, Table 1, p 5 0.001). Patients with
prior lenalidomide or bortezomib exposure collected fewer
CD34(1) stem cells than patients receiving chemotherapy or thalid-
omide based inductions (p 5 0.0001). Patients who received prior
lenalidomide also engrafted slower than patients who received other
induction regimens following HDC/ASCT, independent of
68 Poster Session-ICD34(1) cell dose received (Table 1). Our data expand on previous
work in this area by including data in patients receiving chemother-
apy, thalidomide and bortezomib based inductions. Findings suggest
pre-mobilization marrow plasmacytosis may be a practical, effective
test to determine chances of mobilization success in patients with
prior lenalidomide exposure.
Effects of induction regimen on stem cell mobilization
Type of InductionChemotherapy Thalidomide Lenalidomide Bortezomib vp-
aluePre-mobilization
bone marrow:plasmacytosis,
successfully
mobilized (%)22 14 5 12 0.001plasmacytosis,
failed
mobilization
(%)39 21 23 0.004Apheresis
sessions
(median)2 2 3 2 0.008CD34(1) stem
cell
collection:Day 1 9.9 7.4 3.6 6.1 0.004Total 18 11 8 8 0.0001Engraftment
kinetics:ANC
. 500/uL
(days)9 10 11 10.5 0.003182
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS
AGED $65 YEARS WITH MULTIPLE MYELOMA: MOFFITT CANCER CEN-
TER EXPERIENCE
Paoletti, C.1, Balducci, L.2, Alsina, M.1, Boler, I.2, Popa, M.A.2,
Extermann, M.2, Lara-Rivera, S.2, Raychaudhury, J.1, Anasetti, C.1,
Fernandez, H.1, Sullivan, D.1, Dalton, W.S.1, Field, T.1, Ayala, E.1, Khar-
fan-Dabaja, M.A.1, Perez, L.1, Perkins, J.1, Janssen, W.E.1, Harris, J.1,
Schell, M.3, Kim, J.3, Ochoa-Bayona, J.L.1 1Moffitt Cancer Center, Tampa,
FL; 2Moffitt Cancer Center, Tampa, FL; 3Moffitt Cancer Center, Tampa, FL
ASCT has demonstrated to prolong the survival in Multiple Mye-
loma (MM) patients, but the benefit of this therapy and impact of co-
morbidities for elderly patients has not been well established. We
retrospectively analyzed MM patients aged $ 65 years who under-
went ASCT from 2001 to 2006. We examined a series of clinical pa-
rameters [e.g. age, gender, stage at diagnosis, time from diagnosis to
transplant (TDT), lines of chemotherapy before transplant, response
to first-line therapy, conditioning regimens, incidence and type of
non-hematological toxicities (NHT), and comorbidity] and clinical
outcomes [e.g. time to neutrophils and platelets engraftment, length
of hospital stay (LOS), progression-free survival (PFS), and overall
survival (OS)]. PFS and OS were calculated from the time of trans-
plant to the time of event occurrence. One-hundred and ten patients
(45 F, 65 M), median age 68 (65–77), were eligible. Two thirds had
Durie-Salmon stage III, 31% received more than 1 line of therapy,
and 27% were refractory to first-line therapy. The median TDT
was 8.8 months (2–208). The mean scores for Charlson comorbidity
index, cumulative illness rating scale for geriatrics, and Hemopoietic
Stem cell Transplantation Comorbidity Index, retrospectively calcu-
lated at time of transplant, were 0.6 (0–6), 5 (0–12), and 2 (0–7), re-
spectively. Conditioning regimens were melphalan alone (63%) or
melphalan plus other drugs (37%). The median LOS was 19 days
(0–60). Thirty-seven percent of patients did not develop any grade
4 NHT; the most common grade 4 NHT were infection, mucositis,
and supraventricular arrhythmias. The median number of days to
neutrophils .0.5  109/L and to platelets .20  109/L was 12 (6–40) and 13 (6–187), respectively. TRM at day 100 was 4.5%. Median
PFS and OS were 14.3 (12.2–20.3) and 36.7 months (28.2–45.4), re-
spectively. Multivariate analysis showed male was a significant factor
for time to neutrophil engraftment (HR5 0.64; 95% CI: 0.41–0.99).
Older age (HR 5 0.92; 95% CI: 0.85–0.99) and more toxicities
(HR 5 0.49; 95% CI: 0.38–0.63) were significant predictors for in-
creasing LOS. Longer TDT was significant (HR 5 1.02; 95% CI:
1.00–1.03) for decreasing LOS. No factor was found to be signifi-
cantly predictive for PFS and OS. Comorbidity did not predict PFS
and OS at univariate level. ASCT in MM patients aged $ 65 years
is associated with low peritransplant mortality and manageable
toxicity making it a feasible option for this patient population.183
COMBINATION OF IFN-/GM-CSF AS MAINTENANCE THERAPY FORMULTI-
PLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLAN-
TATION (ASCT): RESULTS OF A PROSPECTIVE PHASE II STUDY
Salmasinia, D., Moreb, J.S. university of Florida, Gainesville, FL
Several studies have shown that maintenance therapy with IFN-
a after ASCT prolongs response duration and may improve survival.
In our experience, up to 30% of the patients are unable to take IFN-
a because of either slow hematopoietic recovery after ASCT or IFN-
induced pancytopenia. In this study, we combined GM-CSF with
IFN-a in order to improve IFN tolerance in post-ASCT myeloma
patients. Primary aims were to evaluate toxicity, long term side ef-
fects, and effectiveness of this combination maintenance therapy.
The treatment (4  106 units of IFN-a and 125 mg/m2 of GM-
CSF) schedule was three times a week (M, W, F) for twelve months.
After that, patients would continue IFN-a at the discretion of the
treating physician. Between January 2003 and June 2007, 27 patients
were enrolled after signing informed consents within 120 days of
ASCT, and four of them had tandem ASCT. Patients with progres-
sive myeloma were excluded from study. One enrolled patient was
excluded from analysis for not taking the drugs. Only one patient dis-
continued treatment due to moderate pancytopenia and two devel-
oped skin rashes/cellulitis related to GM-CSF injections. Seven
others were taken off study due to persistent IFN-related flu-like
symptoms and/or increase in liver enzymes. Median length of treat-
ment with the combination was 11.5 months. Seven patients contin-
ued IFN-a beyond one year, four of whom are still taking it. With
a median follow-up of 44.5 months (n5 26), an intent -to-traet anal-
ysis reveals overall survival (OS) and progression-free survival (PFS)
of 51 and 45 months, respectively. Eleven patients (42%) have re-
mained in VGPR/CR since ASCT. These results were compared
to a historical group of patients (n 5 25) who had a median of 8
months IFN only treatment with PFS of 22 months. In conclusion,
our results demonstrate the effectiveness of GM-CSF in ameliorat-
ing the IFN-induced myelotoxicity and achieving better PFS.184
IMPROVED OUTCOME FOR ALLOGENEIC TRANSPLANTATION
PERFORMED AFTER JANUARY 2000
Pelosini, M., Mendoza, F., Hosing, C., Popat, U.R., Anderlini, P.,
Alousi, A.M., Kebriaei, P., Weber, D.M., Wang, M., Champlin, R.E.,
Giralt, S.A., Qazilbash, M.H. UT - MD Anderson Cancer Center,
Houston, TX
Background: Allogeneic hematopoietic stem cell transplantation
(allo SCT) is a potentially curative approach in patients with multiple
myeloma (MM). The potential benefit is offset by a higher risk of
transplant-related mortality (TRM), graft-vs-host disease (GVHD)
and opportunistic infections. A number of factors including better
supportive care, antimicrobial agents, improvement in HLA typing
and reduced intensity conditioning (RIC) regimens have resulted in
a lower risk of TRM. We evaluated if there was an improvement in
the outcome of patients who received allo SCT for MM after January
1, 2000 compared to patients who received allo SCT before that date.
Methods: 101 patients underwent allo SCT at UT-MDACC be-
tween 11/1985 and 1/2007, with 40 patients undergoing allo SCT
before January 1, 2000 (group A) and 61 after that date (group B).
Median age at allo SCT in Group A and B was 42 and 48 years,
